Additionally, several synthesized agents, such as a topical anesthetic drug dyclonine and an antispasmodic flopropione, have recently been shown to selectively inhibit TRPV3, reduce itching and alleviate skin inflammation for potential drug repurposing (49, 50, 51). The gene discussed is TRPV3; the disease is dermatitis.